🚀 VC round data is live in beta, check it out!
Poltreg Valuation Multiples
Discover revenue and EBITDA valuation multiples for Poltreg and similar public comparables like Gensight Biologics, Active Biotech, AcuCort, Alligator Bioscience and more.
Poltreg Overview
About Poltreg
Poltreg SA is a biotechnology company at the clinical stage developing an innovative generation of medicines using T-regulatory cells (TREGS) in the treatment of autoimmune diseases.
Founded
2015
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$17M
Poltreg Financials
Poltreg reported last 12-month revenue of $2M and negative EBITDA of ($5M).
In the same LTM period, Poltreg generated ($5M) in EBITDA losses and had net loss of ($6M).
Revenue (LTM)
Poltreg P&L
In the most recent fiscal year, Poltreg reported revenue of $97K and EBITDA of ($4M).
Poltreg expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $97K | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($1M) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (1270%) | XXX | XXX | XXX |
| EBITDA | ($5M) | XXX | ($4M) | XXX | XXX | XXX |
| EBITDA Margin | (262%) | XXX | (3962%) | XXX | XXX | XXX |
| EBIT Margin | (444%) | XXX | (5794%) | XXX | XXX | XXX |
| Net Profit | ($6M) | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | (365%) | XXX | (5345%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Poltreg Stock Performance
Poltreg has current market cap of $22M, and enterprise value of $17M.
Market Cap Evolution
Poltreg's stock price is $4.69.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17M | $22M | 0.1% | XXX | XXX | XXX | $-1.12 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPoltreg Valuation Multiples
Poltreg trades at 10.0x EV/Revenue multiple, and (3.8x) EV/EBITDA.
EV / Revenue (LTM)
Poltreg Financial Valuation Multiples
As of April 19, 2026, Poltreg has market cap of $22M and EV of $17M.
Equity research analysts estimate Poltreg's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Poltreg has a P/E ratio of (3.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $22M | XXX | $22M | XXX | XXX | XXX |
| EV (current) | $17M | XXX | $17M | XXX | XXX | XXX |
| EV/Revenue | 10.0x | XXX | 176.3x | XXX | XXX | XXX |
| EV/EBITDA | (3.8x) | XXX | (4.4x) | XXX | XXX | XXX |
| EV/EBIT | (2.3x) | XXX | (3.0x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (13.9x) | XXX | XXX | XXX |
| P/E | (3.5x) | XXX | (4.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Poltreg Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Poltreg Margins & Growth Rates
Poltreg's revenue in the last 12 month grew by 227%.
Poltreg's rule of 40 is 9931% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Poltreg's rule of X is 24856% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Poltreg Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 227% | XXX | (43%) | XXX | XXX | XXX |
| EBITDA Margin | (262%) | XXX | (3962%) | XXX | XXX | XXX |
| EBITDA Growth | (76%) | XXX | 54% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 9931% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 24856% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 242% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1027% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 4524% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Poltreg Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Poltreg | XXX | XXX | XXX | XXX | XXX | XXX |
| Gensight Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Active Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| AcuCort | XXX | XXX | XXX | XXX | XXX | XXX |
| Alligator Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanogroup | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Poltreg M&A Activity
Poltreg acquired XXX companies to date.
Last acquisition by Poltreg was on XXXXXXXX, XXXXX. Poltreg acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Poltreg
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPoltreg Investment Activity
Poltreg invested in XXX companies to date.
Poltreg made its latest investment on XXXXXXXX, XXXXX. Poltreg invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Poltreg
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Poltreg
| When was Poltreg founded? | Poltreg was founded in 2015. |
| Where is Poltreg headquartered? | Poltreg is headquartered in Poland. |
| Is Poltreg publicly listed? | Yes, Poltreg is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Poltreg? | Poltreg trades under PTG ticker. |
| When did Poltreg go public? | Poltreg went public in 2021. |
| Who are competitors of Poltreg? | Poltreg main competitors are Gensight Biologics, Active Biotech, AcuCort, Alligator Bioscience. |
| What is the current market cap of Poltreg? | Poltreg's current market cap is $22M. |
| What is the current revenue of Poltreg? | Poltreg's last 12 months revenue is $2M. |
| What is the current revenue growth of Poltreg? | Poltreg revenue growth (NTM/LTM) is 227%. |
| What is the current EV/Revenue multiple of Poltreg? | Current revenue multiple of Poltreg is 10.0x. |
| Is Poltreg profitable? | No, Poltreg is not profitable. |
| What is the current EBITDA of Poltreg? | Poltreg has negative EBITDA and is not profitable. |
| What is Poltreg's EBITDA margin? | Poltreg's last 12 months EBITDA margin is (262%). |
| What is the current EV/EBITDA multiple of Poltreg? | Current EBITDA multiple of Poltreg is (3.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.